HLA-DR Antigen Expression in Colorectal Carcinomas: Influence of Expression by IFN-gamma in Situ and Its Association with Tumour Progression

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Mar 1

PMID 8605101

Citations 10

Authors

K Matsushita

T Takenouchi

S Kobayashi

H Hayashi

K Okuyama

T Ochiai

A Mikata

K Isono

Affiliations

Soon will be listed here.

Abstract

The authors attempted to investigate the host's immune response against colorectal carcinoma through the expression of HLA-DR antigen on carcinoma cells (Ca) on normal epithelia immediately adjacent to carcinoma (AN) in relation to tumour progression. The expression of HLA-DR antigen on Ca and on normal epithelia, both on AN and those 5-10 cm removed from the carcinoma (RN), were examined immunohistochemically. mRNAs of cytokines, IFN-gamma and TNF-alpha, were detected by reverse transcription-polymerase chain reaction (RT-PCR) in both carcinoma and remote normal tissues. The expression of HLA-DR antigen on AN was significantly increased compared with RN. Patients with tumours showing HLA-DR staining both in Ca and AN were in less advanced Dukes' stages (Dukes' A or B) compared with those without the stain. Furthermore, the expression of HLA-DR antigen in normal mucosa coincided significantly with the existence of IFN-gamma mRNA. Detection in carcinoma tissues of IFN-gamma mRNA that leads to the induction of HLA-DR antigen on AN could be an indicator of a host's immune response to carcinoma. These in vivo observations might be clinically applicable to the prediction of patients' immune responsiveness to carcinomas.

Citing Articles

Anti-FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer.

Kobayashi S, Hiwasa T, Ishige T, Kano M, Hoshino T, Rahmutulla B Cancer Sci. 2020; 112(2):847-858.

PMID: 33306856 PMC: 7894018. DOI: 10.1111/cas.14767.

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.

Sabbatino F, Liguori L, Polcaro G, Salvato I, Caramori G, Salzano F Int J Mol Sci. 2020; 21(19).

PMID: 33023239 PMC: 7582904. DOI: 10.3390/ijms21197295.

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Balhorn R, Balhorn M Oncotarget. 2020; 11(35):3315-3349.

PMID: 32934776 PMC: 7476732. DOI: 10.18632/oncotarget.27709.

CD14 and IL18 gene polymorphisms associated with colorectal cancer subsite risks among atomic bomb survivors.

Hu Y, Yoshida K, Cologne J, Maki M, Morishita Y, Sasaki K Hum Genome Var. 2016; 2:15035.

PMID: 27081544 PMC: 4785571. DOI: 10.1038/hgv.2015.35.

Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B Neuro Oncol. 2015; 17(11):1486-96.

PMID: 25825052 PMC: 4648300. DOI: 10.1093/neuonc/nov045.

References

Moller P, Momburg F, Koretz K, Moldenhauer G, Herfarth C, Otto H . Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 1991; 51(2):729-36. View

McDougall C, Ngoi S, Goldman I, Godwin T, Felix J, DECOSSE J . Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res. 1990; 50(24):8023-7. View

Watanabe Y, Jacob C . Regulation of MHC class II antigen expression. Opposing effects of tumor necrosis factor-alpha on IFN-gamma-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell. J Immunol. 1991; 146(3):899-905. View

James R, Edwards S, Hui K, Bassett P, Grosveld F . The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology. 1991; 72(2):213-8. PMC: 1384486. View

Gumina R, DeYoung L, Webb D, Devens B . Transduction of the IFN-gamma signal for HLA-DR expression in the promonocytic line THP-1 involves a late-acting PKC activity. Cell Immunol. 1991; 138(2):265-79. DOI: 10.1016/0008-8749(91)90152-2. View

Tomoda T, Kurashige T, Taniguchi T . Stimulatory effect of interleukin-1 beta on the interferon-gamma-dependent HLA-DR production. Immunology. 1992; 76(1):15-9. PMC: 1421747. View

Mizoguchi H, Oshea J, Longo D, Loeffler C, McVicar D, Ochoa A . Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992; 258(5089):1795-8. DOI: 10.1126/science.1465616. View

Andersen S, Rognum T, Lund E, Meling G, Hauge S . Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer. 1993; 68(1):80-5. PMC: 1968312. DOI: 10.1038/bjc.1993.290. View

Lahat N, Sobel E, Kraiem Z . Control of HLA-DR antigen expression by gamma-interferon: separate signal transduction mechanisms in malignant and nonmalignant human thyroid cells. Cancer Res. 1993; 53(17):3943-7. View

10.

Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H . Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993; 53(23):5610-2. View

11.

Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern P . Natural history of HLA expression during tumour development. Immunol Today. 1993; 14(10):491-9. DOI: 10.1016/0167-5699(93)90264-L. View

12.

Watt A, House A . Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer. 1978; 41(1):279-82. DOI: 10.1002/1097-0142(197801)41:1<279::aid-cncr2820410139>3.0.co;2-b. View

13.

Chirgwin J, Przybyla A, MacDonald R, Rutter W . Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18(24):5294-9. DOI: 10.1021/bi00591a005. View

14.

Hsu S, RAINE L, FANGER H . Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80. DOI: 10.1177/29.4.6166661. View

15.

Koide Y, Awashima F, YOSHIDA T, Takenouchi T, Wakisaka A, Moriuchi J . The role of three distinct Ia-like antigen molecules in human T cell proliferative responses: effect of monoclonal anti-Ia-like antibodies. J Immunol. 1982; 129(3):1061-9. View

16.

Selby W, Janossy G, Mason D, Jewell D . Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol. 1983; 53(3):614-8. PMC: 1535633. View

17.

Lampert I, Kirkland S, Farrell S, Borysiewicz L . HLA-DR expression in a human colonic carcinoma cell line. J Pathol. 1985; 146(4):337-44. DOI: 10.1002/path.1711460407. View

18.

Sugarman B, Aggarwal B, Hass P, Figari I, Palladino Jr M, Shepard H . Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985; 230(4728):943-5. DOI: 10.1126/science.3933111. View

19.

Dinarello C, Mier J . Lymphokines. N Engl J Med. 1987; 317(15):940-5. DOI: 10.1056/NEJM198710083171506. View

20.

Rognum T, Brandtzaeg P, Elgjo K, Fausa O . Heterogeneous epithelial expression of class II (HLA-DR) determinants and secretory component related to dysplasia in ulcerative colitis. Br J Cancer. 1987; 56(4):419-24. PMC: 2001837. DOI: 10.1038/bjc.1987.217. View